Pacific 8 Ventures

Pacific 8 Ventures is a venture capital firm that invests at the nexus of disruptive technology platforms and healthcare. They focus on seed-stage investments and prefer to be the first institutional investor. Their primary focus is on disruptive technology platforms transforming therapeutics, diagnostics, and broader health services. Geographically, they primarily target the U.S. market, which they consider the largest for emerging disruptive innovations.

Their recent investments include Elsa Fertility, Matrisome Bio, Certainly Health, Empirical Health, Laguna Bio, Mammoth Biosciences, Bunkerhill, BillionToOne, Interface Biosciences, Fauna Bio, and Dorian Therapeutics. These companies span various sectors within healthcare and technology, reflecting Pacific 8 Ventures' commitment to advancing innovative solutions in the industry.

The firm's team comprises professionals with extensive experience in healthcare technology and venture capital. For instance, Ser-Chen, MD, brings over 10 years of clinical experience and serves as a faculty member at Tzu-Chi University in Taiwan. Jack has more than 15 years of experience in the healthcare technology space, having led sales and built strategic alliances in the Northeast America region. Chris has over 15 years of experience in venture capital and technology transformations in the U.S. and Asia, with a focus on consumer health, technology, and education investments.

Pacific 8 Ventures' strategic approach combines financial investment with strategic partnerships, leveraging their network to provide market access for portfolio companies. This approach underscores their commitment to fostering innovation and growth in the healthcare sector through targeted investments and collaborative partnerships.